Evidence map›Paper›PMID 41918029›Full record

ArticleJournal of cheminformatics2026

A novel approach for enhancing the potency of kinase inhibitors using topological water networks.

Re Gin Jeoung, Anand Balupuri, Nayoung Lim, Sungwook Choi, Nam Sook Kang

Abstract read
In one paragraph

Article in Journal of cheminformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Re Gin JeoungGraduate School of New Drug Discovery and Development, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon, 34134, Republic of Korea.
Anand BalupuriGraduate School of New Drug Discovery and Development, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon, 34134, Republic of Korea.
Nayoung LimGraduate School of New Drug Discovery and Development, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon, 34134, Republic of Korea.
Sungwook ChoiGraduate School of New Drug Discovery and Development, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon, 34134, Republic of Korea.
Nam Sook KangGraduate School of New Drug Discovery and Development, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon, 34134, Republic of Korea. nskang@cnu.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Optimizing the potency of kinase inhibitors remains a major challenge due to the structural conservation of kinase binding pockets. While several computational methods have been developed to address this issue, most overlook the crucial role of water molecules within the binding site. Our research aims to address this gap by examining topological water networks (TWNs) within the target protein. We identified specific TWN-derived patterns in kinase binding sites which align with known crystallographic kinase fragments. Our findings reveal the potential of TWNs to significantly improve the identification and optimal placement of promising fragments within protein binding sites. Here, we propose TWN-based fragment growing (TWN-FG) method that enhances kinase inhibitor potency by leveraging the topological characteristics of hydration networks. TWN-FG successfully explains structure-activity relationship (SAR) trends of known kinase inhibitors and has been applied to design and synthesize a potent mixed lineage kinase 1 (MLK1) inhibitor. The source code is available at https://github.com/RgJeoung/TWN-FG to support further research and application.

Indexed as

Fragment growingKinase inhibitorsMLK1Protein kinaseWater network

Identifiers

PMID41918029
PMCPMC13162392

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.